CA2859985C - Anti-cancer compounds targeting ral gtpases and methods of using the same - Google Patents

Anti-cancer compounds targeting ral gtpases and methods of using the same Download PDF

Info

Publication number
CA2859985C
CA2859985C CA2859985A CA2859985A CA2859985C CA 2859985 C CA2859985 C CA 2859985C CA 2859985 A CA2859985 A CA 2859985A CA 2859985 A CA2859985 A CA 2859985A CA 2859985 C CA2859985 C CA 2859985C
Authority
CA
Canada
Prior art keywords
mmol
equ
aryl
ethanol
ral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2859985A
Other languages
English (en)
French (fr)
Other versions
CA2859985A1 (en
Inventor
Dan Theodorescu
Michael Fitzpatrick Wempe
David Ross
Samy MEROUEH
Martin A. Schwartz
Phillip REIGAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
UVA Licensing and Ventures Group
Indiana University Research and Technology Corp
Original Assignee
University of Colorado Boulder
Indiana University Research and Technology Corp
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder, Indiana University Research and Technology Corp, University of Virginia Patent Foundation filed Critical University of Colorado Boulder
Publication of CA2859985A1 publication Critical patent/CA2859985A1/en
Application granted granted Critical
Publication of CA2859985C publication Critical patent/CA2859985C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2859985A 2011-12-21 2012-12-21 Anti-cancer compounds targeting ral gtpases and methods of using the same Active CA2859985C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578869P 2011-12-21 2011-12-21
US61/578,869 2011-12-21
PCT/US2012/071341 WO2013096820A1 (en) 2011-12-21 2012-12-21 Anti-cancer compounds targeting ral gtpases and methods of using the same

Publications (2)

Publication Number Publication Date
CA2859985A1 CA2859985A1 (en) 2013-06-27
CA2859985C true CA2859985C (en) 2020-11-03

Family

ID=48669550

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2859985A Active CA2859985C (en) 2011-12-21 2012-12-21 Anti-cancer compounds targeting ral gtpases and methods of using the same

Country Status (8)

Country Link
US (3) US9353121B2 (OSRAM)
EP (1) EP2793881B1 (OSRAM)
JP (1) JP6473330B2 (OSRAM)
KR (1) KR102097343B1 (OSRAM)
CN (1) CN104271132B (OSRAM)
AU (1) AU2012358317B2 (OSRAM)
CA (1) CA2859985C (OSRAM)
WO (1) WO2013096820A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271132B (zh) 2011-12-21 2018-01-12 科罗拉多大学董事会法人团体 靶向Ral GTP酶的抗癌化合物及使用其的方法
US10202397B2 (en) * 2014-07-10 2019-02-12 The Regents Of The University Of Colorado, A Body Corporate Anti-cancer compounds targeting Ral GTPases and methods of using the same
AU2015317321B2 (en) 2014-09-19 2020-03-12 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
PL3447050T3 (pl) 2014-09-19 2020-07-27 Forma Therapeutics, Inc. Chinolinonowe pochodne pirydyn-2(1H)-onu jako inhibitory zmutowanej dehydrogenazy izocytrynianowej
WO2016049500A1 (en) 2014-09-25 2016-03-31 Duke University Kinase inhibitors and related methods of use
WO2016145252A1 (en) * 2015-03-10 2016-09-15 The Trustees Of Princeton University Shmt inhibitors
WO2016205460A1 (en) * 2015-06-16 2016-12-22 Nantbioscience, Inc. Polycyclic derivatives targeting ral gtpases and their therapeutical applications
ES2936827T3 (es) 2016-06-22 2023-03-22 Univ Vanderbilt Moduladores alostéricos positivos del receptor muscarínico de acetilcolina M4
US10077273B2 (en) 2016-09-14 2018-09-18 The Trustees Of Princeton University SHMT inhibitors
US10947241B2 (en) 2016-10-28 2021-03-16 Seoul National University Hospital Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same
CN109890388B (zh) 2016-11-07 2023-03-28 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
WO2018085808A1 (en) 2016-11-07 2018-05-11 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP3544961B1 (en) 2016-11-07 2021-08-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN110024421B (zh) 2016-11-23 2020-12-25 瑞典爱立信有限公司 用于自适应控制去相关滤波器的方法和装置
MA51036A (fr) 2017-12-05 2021-03-17 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
WO2019142192A1 (en) 2018-01-17 2019-07-25 Gavish-Galilee Bio Applications Ltd. New methionine metabolic pathway inhibitors
BR112020014561A2 (pt) 2018-01-17 2020-12-08 Migal - Galilee Research Institute Ltd. Nibidores inovadores da via metabólica da metionina
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
PT3720442T (pt) 2018-05-16 2023-03-13 Forma Therapeutics Inc Inibição de idh-1 mutante
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
CN109305972B (zh) * 2018-09-27 2021-07-09 广州医科大学 一种二氢吡喃并吡唑类化合物及其制备方法和应用
CN109734676B (zh) * 2019-01-16 2021-01-29 四川大学 苯并二氮杂卓类衍生物及其制备方法和应用
EP4076416A4 (en) * 2019-12-19 2024-04-10 The Trustees of Indiana University Small-molecule covalent inhibition of ral gtpases
CN111406752B (zh) * 2020-04-23 2021-07-23 中国农业科学院植物保护研究所 二氢吡咯并吡唑酮类衍生物作为几丁质酶抑制剂或杀线虫剂的应用
WO2022040005A1 (en) * 2020-08-17 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Profilin1:actin inhibitor an anti-angiogenic compound
KR20230133274A (ko) * 2020-11-18 2023-09-19 텍사스 테크 유니버시티 시스템 Ral 상호작용 단백질에 결합하고 이를 억제하는 소분자를 사용하는 암에 대한 요법
US20240325374A1 (en) * 2021-07-23 2024-10-03 The Research Institute At Nationwide Children's Hospital Inhibiting intracellular pathogens
WO2023150793A1 (en) * 2022-02-07 2023-08-10 Cornell University Inhibitors of malic enzyme 1
CN120168481B (zh) * 2025-05-14 2025-08-19 天津医科大学 一种抑制REXO4消解R-loop酶活性的小分子及其在制备肿瘤药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US362503A (en) * 1887-05-10 Sectional boat
US361185A (en) * 1887-04-12 Poueths to john h
US4555396A (en) * 1982-12-22 1985-11-26 Eastman Kodak Company Use of pyrylium and thiapyrylium compounds as biological stains
US5750550A (en) * 1995-09-15 1998-05-12 Sanofi 2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof
JPH10279480A (ja) * 1997-04-07 1998-10-20 Mitsubishi Chem Corp 皮膚組織障害の予防・治療剤
DE19910363B4 (de) 1998-03-10 2007-08-30 Mitsubishi Paper Mills Ltd. Positives, lichtempfindliches bebilderbares Element
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
WO2005020784A2 (en) 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
AU2004262369A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
JPWO2006126625A1 (ja) * 2005-05-25 2008-12-25 田辺三菱製薬株式会社 ピラゾロン誘導体を含む医薬
EP1920048A4 (en) * 2005-07-29 2009-12-09 Childrens Hosp Medical Center GTASE INHIBITORS AND USE METHOD AND CRYSTAL STRUCTURE OF RAC-1 GTASE
CA2620777A1 (en) 2005-09-02 2007-03-08 Tibotec Pharmaceuticals Ltd. Benzodiazepines as hcv inhibitors
US20090221568A1 (en) 2005-11-04 2009-09-03 Jared Shaw Synthesis of Inhibitors of FtsZ
US20070203224A1 (en) 2006-01-09 2007-08-30 University Of Southern California Small-molecules for treating cancer and abnormal cell proliferation disorders
WO2008143894A2 (en) * 2007-05-14 2008-11-27 Dana-Farber Cancer Institute, Inc. Phosphorylated rala
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011010715A1 (ja) 2009-07-24 2011-01-27 国立大学法人 東京大学 Ｐr－Ｓｅｔ７阻害剤
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
US8673913B2 (en) 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
WO2012078902A2 (en) 2010-12-08 2012-06-14 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2013096852A1 (en) 2011-12-21 2013-06-27 The Regents Of The University Of Colorado Biomarkers of cancer
CN104271132B (zh) 2011-12-21 2018-01-12 科罗拉多大学董事会法人团体 靶向Ral GTP酶的抗癌化合物及使用其的方法
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
EP2858981A1 (en) * 2012-06-06 2015-04-15 Basf Se Pyrazolopyrans having herbicidal and pharmaceutical properties
CN103910737B (zh) 2014-03-25 2016-08-17 浙江师范大学 手性的1,4-二氢吡喃(2,3-c)吡唑衍生物及其合成方法和应用

Also Published As

Publication number Publication date
AU2012358317A1 (en) 2014-07-17
US20160280715A1 (en) 2016-09-29
US10689392B2 (en) 2020-06-23
US9353121B2 (en) 2016-05-31
US20200270263A1 (en) 2020-08-27
US11964985B2 (en) 2024-04-23
CN104271132B (zh) 2018-01-12
JP2015503507A (ja) 2015-02-02
KR102097343B1 (ko) 2020-04-07
WO2013096820A1 (en) 2013-06-27
US20140315894A1 (en) 2014-10-23
CA2859985A1 (en) 2013-06-27
AU2012358317B2 (en) 2017-12-14
EP2793881A4 (en) 2015-05-20
KR20150010696A (ko) 2015-01-28
EP2793881B1 (en) 2018-10-31
EP2793881A1 (en) 2014-10-29
CN104271132A (zh) 2015-01-07
JP6473330B2 (ja) 2019-02-20

Similar Documents

Publication Publication Date Title
CA2859985C (en) Anti-cancer compounds targeting ral gtpases and methods of using the same
USRE48557E1 (en) Anti-cancer compounds targeting Ral GTPases and methods of using the same
US9938245B2 (en) Carbonyl erastin analogs and their use
CA3194868A1 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2018001084A1 (zh) 热休克蛋白抑制剂及其制备方法和应用
BR112020000564A2 (pt) novos derivados de heteroarilamida como inibidores seletivos das histonas desacetilases 1 e/ou 2 (hdac1-2)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170925